骨髄異形成症候群（MDS）治療薬の世界市場2015-2019...市場調査レポートについてご紹介

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Product profile
• REVLIMID
• VIDAZA
• Dacogen
• Glivec/Gleevec

PART 04: Market research methodology
• Research methodology
• Economic indicators

PART 05: Introduction
• Key market highlights

PART 06: Disease overview
• Understanding the disease
• Risk factors
• Signs and symptoms
• Pathophysiology
• Types
• Diagnosis
• Epidemiology
• Treatment

PART 07: Pipeline portfolio
• Information on pipeline candidates

PART 08: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 09: Market segmentation by drug class
• Alkylating agents
• Cytotoxic antibiotics
• Topoisomerase inhibitors
• Others

PART 10: Market segmentation by route of administration
• Oral
• Parenteral

PART 11: Geographical Segmentation
• Myelodysplastic syndrome market in EMEA
• Myelodysplastic syndrome market in APAC

PART 12: Market drivers
• Rise in aging population
• Unmet medical needs
• Use of diagnostic tools

PART 13: Impact of drivers

PART 14: Market challenges
• Use of off-label drugs
• Adverse effects of drugs
• High cost of drugs

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Rise in public awareness
• Patient assistance programs
• Increase in R&D
• Intense competition

PART 17: Vendor landscape
• Competitive scenario
• Market share analysis 2014
• Other prominent vendors

PART 18: Key vendor analysis
• Celgene
• Novartis
• Otsuka Holdings

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Myelodysplastic syndrome: Risk factors
Exhibit 03: Myelodysplastic syndrome: Signs and symptoms
Exhibit 04: History of myelodysplastic syndrome classification system
Exhibit 05: FAB classification system: Types of myelodysplastic syndrome
Exhibit 06: WHO classification system: Types of myelodysplastic syndrome
Exhibit 07: IPSS classification: Factors and score
Exhibit 08: IPSS-R classification: Cytogenetic score
Exhibit 09: IPSS-R classification: Score values
Exhibit 10: IPSS-R classification: Risk categories and scores
Exhibit 11: Diagnostic tests for myelodysplastic syndrome
Exhibit 12: Myelodysplastic syndrome: Global incidence based on age 2007-2011 (years)
Exhibit 13: Myelodysplastic syndrome: Incidence in US by race 2007-2011
Exhibit 14: Treatment options for myelodysplastic syndrome
Exhibit 15: Chemotherapeutic agents
Exhibit 16: Immunotherapy drugs
Exhibit 17: Supportive therapy for myelodysplastic syndrome
Exhibit 18: Drugs that received orphan designation for treatment of myelodysplastic syndrome
Exhibit 19: Myelodysplastic syndrome: Drug pipeline
Exhibit 20: Global myelodysplastic syndrome market ($ millions)
Exhibit 21: Five forces analysis
Exhibit 22: Global myelodysplastic syndrome market segmentation by drug class
Exhibit 23: Global myelodysplastic syndrome market segmentation by route of administration
Exhibit 24: Global myelodysplastic syndrome market segmentation by geography 2014
Exhibit 25: Myelodysplastic syndrome market in Americas 2014-2019 ($ millions)
Exhibit 26: Myelodysplastic syndrome market in EMEA 2014-2019 ($ millions)
Exhibit 27: Myelodysplastic syndrome market in APAC 2014-2019 ($ millions)
Exhibit 28: Global myelodysplastic syndrome market segmentation by geography 2014-2019 ($ millions)
Exhibit 29: Impact of drivers
Exhibit 30: Impact of drivers and challenges
Exhibit 31: Ranking of leading companies
Exhibit 32: Celgene: YoY growth and revenue of VIDAZA 2012-2014 ($ millions)
Exhibit 33: Celgene: YoY growth and revenue of REVLIMID 2012-2014 ($ billions)
Exhibit 34: Celgene: Key takeaways
Exhibit 35: Otsuka Holdings: Key takeaways
Exhibit 36: Novartis: Key takeaways
Exhibit 37: Celgene: Product segmentation by revenue 2014
Exhibit 38: Celgene: Product segmentation by revenue 2013 and 2014
Exhibit 39: Celgene: Geographical segmentation by revenue 2014
Exhibit 40: Novartis: Business segmentation by revenue 2014
Exhibit 41: Novartis: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 42: Novartis: Geographical segmentation by revenue 2014
Exhibit 43: Otsuka Holdings: Business segmentation by revenue 2014
Exhibit 44: Otsuka Holdings: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 45: Otsuka Holdings: Geographical segmentation by revenue 2014